You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药与礼来扩展治疗肿瘤抑制剂中国商业化合作
阿思达克 07-29 09:29
和黄中国医药科技公布,集团联同礼来公司就2013年与礼来上海签订的爱优特许可和合作协定达成了一项修正案。是次协议进一步扩展和黄医药对爱优特在中国商业化过程中的职责。自今年10月1日起,和黄医药将通过旗下超过320名员工的肿瘤商业化团队,负责开发和执行爱优特在中国市场的所有医学资讯沟通、推广以及本地和区域市场活动。

该药是一种高选择性强效口服血管内皮生长因数受体(VEGFR)1、2及3的抑制剂。VEGFR 抑制剂在抑制肿瘤的血管生成中起到重要作用。

另外,和黄医药亦获中国国家药品监督管理局将沃利替尼(savolitinib)新药上市申请纳入优先审评,是沃利替尼在全球范围内的首个新药上市申请,也是中国首个选择性MET抑制剂新药上市申请。沃利替尼的全球开发计划包括非小细胞肺癌与肾癌,并且正在探索用於治疗其他MET驱动的肿瘤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account